Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruitingRare disease

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Featured sites

Sites that work closely with us on this trial

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study is being done in people with Asthma to compare two inhaled treatments and see which one may provide better control of the disease over time. The treatments are Trimbow 87/5/9, which contains beclometasone dipropionate, glycopyrronium bromide, and formoterol fumarate dihydrate, and Fostair 200/6, which contains beclometasone dipropionate and formoterol fumarate dihydrate. Beclometasone is a steroid medicine that helps reduce swelling in the airways, formoterol helps open the airways, and glycopyrronium helps keep the airways open for longer.

The study is planned to last about 12 months for each person. It compares the two inhaled medicines in a random way, and the treatment is given through an inhaler. During the study, asthma symptoms and general control of asthma are checked at several visits, and the treatment is continued while these checks are done. The main purpose of the study is to see whether Trimbow works at least as well as Fostair for asthma control.

The study also looks at how often people have worse asthma attacks, how often they need steroid tablets by mouth, and whether breathing and quality of life change during the study. Safety is also watched throughout the treatment period.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Study start

    After you join the study, you are assigned to one of two treatment groups in a random way. This means the treatment is chosen by chance, not by choice.

    The study is open-label, which means you and the study staff know which inhaler you are using.

  2. Step 2

    Treatment period

    You use one inhaler treatment for 12 months.

    One possible treatment is Trimbow 87 micrograms/5 micrograms/9 micrograms, which contains beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide. It is taken by inhalation. The stated dose is 400 micrograms per administration.

    The other possible treatment is Fostair 200 microgram/6 microgram per actuation, which contains formoterol fumarate dihydrate and beclometasone dipropionate anhydrous. It is taken by inhalation. The stated dose is 800 micrograms per administration.

    The study records how your asthma control changes during this 12-month period.

  3. Step 3

    Study visits and assessments

    You attend study visits during the treatment period, including a visit at month 12.

    At the visits, your asthma control is checked using the Asthma Control Questionnaire-5 (ACQ-5). This is a short questionnaire about how well your asthma is controlled.

    Your breathing is measured with spirometry, which is a test that measures how much air you can breathe out and how fast you can breathe it out.

    Your breathing may also be measured with oscillometry, which is a test that checks how air moves through your airways.

    Blood or other test results may be used to check eosinophils, which are a type of blood cell linked to allergy and asthma.

    You complete questionnaires about inhaler use, quality of life, and asthma symptoms, including the Test of the Adherence to Inhalers, the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L), and the chronic airways assessment test.

    The study also records whether you have asthma flare-ups, including severe and moderate flare-ups. A flare-up means your asthma gets worse.

    The study records whether you need oral systemic corticosteroids. These are steroid medicines taken by mouth to reduce inflammation.

    The study also records safety information, including cardiovascular events, which involve the heart or blood vessels, and any serious or fatal events.

  4. Step 4

    Monitoring during the 12-month period

    During the 12 months, the study checks how long it takes before your first severe asthma flare-up and your first moderate or severe asthma flare-up.

    The study also records the number of days you use oral systemic corticosteroids and the total dose you take during the treatment period.

    Your asthma control, breathing test results, and questionnaire answers are compared with your starting results over time.

  5. Step 5

    Month 6 assessment

    At 6 months, the study checks your asthma control and other measured results again.

    The study looks at whether you meet the definition of partial clinical asthma remission or complete clinical asthma remission at this timepoint.

    Complete clinical asthma remission means: no oral steroid use at that time, no severe asthma flare-up before that time, an ACQ-5 score of 1.5 or lower, and no decrease in the breathing test result called forced expiratory volume in 1 second after using the inhaler. This breathing test result shows how much air you can force out in one second.

    Partial clinical asthma remission means: no oral steroid use at that time, and two of the other three remission conditions are met.

  6. Step 6

    Month 12 assessment and end of treatment period

    At 12 months, you have the final study assessment for the main outcome of the trial.

    The main result is the change in ACQ-5 from the start of the study to month 12.

    The study again checks asthma flare-ups, breathing test results, questionnaire answers, eosinophils, use of oral systemic corticosteroids, and safety information.

    The study also checks whether you meet the definitions of partial clinical asthma remission or complete clinical asthma remission at 12 months.

Who can join the trial?

11 criteria

  • Written informed consent must be given before any study procedure. This means the person must sign a form showing they understand the study and agree to take part.
  • Adults only: the participant must be a male or female aged 18 years or older.
  • The participant must have a doctor-confirmed asthma diagnosis, documented according to usual medical practice.
  • The participant must have had stable asthma treatment for at least 3 months before randomization. Randomization means being assigned to a study treatment by chance.
  • The participant must have poor asthma control at the time of randomization, shown by an ACQ-5 score of 1.5 or higher and at least 1 asthma exacerbation in the previous year. An exacerbation means a flare-up or worsening of asthma.
  • Women who can become pregnant and their male partners with fertility must be willing to use a highly effective birth control method from the time the consent form is signed until the last study visit.
  • The participant must be able to cooperate with the study and be trained to use the patient app correctly.
  • The participant must be able to complete the required study measurements, including electronic patient-reported outcomes (ePRO), which are answers the patient enters electronically about their health and symptoms.
  • The participant must be able to understand the risks involved in taking part.
  • Participants with asthma may still be included if they do not have a clinically relevant diagnosis of chronic obstructive pulmonary disease (COPD), which is a long-term lung disease that makes breathing difficult.
  • Participants using maintenance and reliever therapy may be included if the daily dose of inhaled corticosteroid (ICS) does not exceed 400 micrograms per day of beclometasone or an equivalent dose. An ICS is a steroid medicine breathed into the lungs to reduce inflammation.

Who cannot join the trial?

6 criteria

  • Taking part in another interventional clinical trial at the same time. An interventional clinical trial is a study where the treatment is actively given or changed.
  • Being pregnant or breastfeeding at the time of joining the study.
  • Having another chronic respiratory disease, which means a long-lasting lung or breathing disease, such as lung cancer, alpha1-antitrypsin deficiency (a missing or low protective protein that can harm the lungs), active tuberculosis (a contagious infection that mainly affects the lungs), clinically significant bronchiectasis (permanent widening and damage of the airways that is important enough to affect health), interstitial lung disease (scarring or inflammation in the lung tissue), pulmonary hypertension (high blood pressure in the blood vessels of the lungs), or any other uncontrolled or medically important disease that the study doctor thinks would interfere with the study.
  • Having a medical reason that makes the use of long-acting muscarinic antagonists unsafe. These are medicines that help keep the airways open for a long time.
  • Using biological therapy for asthma. Biological therapy means treatment made from living cells or proteins, often given by injection or infusion.
  • For people in France only: being under court protection, including protected adults, or not being linked to the French social security system.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Trimbow

    is an inhaled medicine used in the study as the test treatment for asthma. It contains three medicines in one inhaler: a steroid to help reduce swelling and irritation in the airways, a long-acting bronchodilator to help keep the airways open, and another bronchodilator that relaxes the muscles around the airways. The goal is to see whether this single inhaler works at least as well as the comparison treatment for helping people control their asthma.

  • Fostair

    is an inhaled medicine used in the study as the comparison treatment for asthma. It contains two medicines in one inhaler: a steroid to reduce inflammation in the airways and a long-acting bronchodilator to help keep the airways open. It is used to compare how well it controls asthma symptoms and how safe it is compared with the test inhaler.

What is already known about the treatment

  • Fostair 200 microgram/6 microgram per actuation pressurised inhalation solution

    This medicine is a pressurised inhalation solution used with an inhaler, so the dose is breathed directly into the lungs. It is a well-known and widely used treatment in medical practice and medical literature for asthma control, especially when a steroid plus a long-acting bronchodilator is needed. It contains beclometasone dipropionate, a steroid that lowers swelling and irritation in the airways, and formoterol fumarate dihydrate, a long-acting medicine that relaxes the airway muscles by acting on beta-2 receptors; together, they help make breathing easier and reduce asthma symptoms. It is classified as an inhaled corticosteroid and long-acting beta-2 agonist combination medicine for asthma.

  • Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

    This medicine is a pressurised inhalation solution used by inhalation through an inhaler, delivering the drug directly to the lungs. It is a newer but already established medicine in current medical practice and literature for asthma treatment, especially in people who need stronger control with a three-part inhaled therapy. It contains beclometasone dipropionate, which reduces airway swelling, formoterol fumarate dihydrate, which helps open the airways by relaxing muscle around them, and glycopyrronium bromide, which blocks signals that tighten the airways; together, these actions help improve breathing and reduce flare-ups. It is classified as a triple inhaled therapy combining an inhaled corticosteroid, a long-acting beta-2 agonist, and a long-acting muscarinic antagonist.

Investigated diseases

Asthma - Asthma is a long-term disease of the airways that causes them to become swollen and extra sensitive. The airways can narrow and produce more mucus, which leads to repeated episodes of wheezing, shortness of breath, chest tightness, and coughing. Its course often changes over time, with symptom-free periods followed by flare-ups. In some people, the symptoms remain mild, while in others they become more frequent or persistent.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2025-524289-56-00Protocol codeCLI-05993AB1-08Estimated enrolment644 patientsSponsorChiesi Farmaceutici S.p.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).